Menu
← Oncology Approval Tracker
FDA DECISION ·
Lynparza + bevacizumab
olaparib + bevacizumab · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line maintenance for adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in response to platinum chemotherapy whose tumors were homologous recombination deficiency positive, based on BRCA mutation or genomic instability on an approved test.
LAMPGEN ANALYSIS
Why it matters
Added a biomarker-defined maintenance combination after first-line platinum treatment.
What research teams should watch
Arrange HRD testing early and reconcile planned bevacizumab and oral therapy schedules.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Biomarker-selected first-line maintenancePRIMARY RECORDS